Sagimet Biosciences is a technology company.
Sagimet Biosciences has raised $194.0M across 7 funding rounds.
Sagimet Biosciences has raised $194.0M in total across 7 funding rounds.
Sagimet Biosciences Inc. (SGMT) is a clinical-stage biopharmaceutical company developing selective fatty acid synthase (FASN) inhibitors to treat diseases driven by dysfunctional lipid metabolism, such as metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), acne, and certain cancers.[1][2][3] Its lead candidate, denifanstat, is an oral, once-daily pill targeting MASH with moderate to advanced liver fibrosis; it has shown positive results in Phase 2 trials (FASCINATE-1 and FASCINATE-2), received FDA Breakthrough Therapy designation, and completed end-of-Phase 2 interactions to advance toward Phase 3.[3] The company serves patients with metabolic, dermatological, and oncological conditions where excess palmitate production plays a key role, addressing unmet needs in fibrosis and lipid dysregulation; it also advances TVB-3567 for acne and oncology programs for solid tumors and glioblastoma, with early traction via in-house discovery and partnerships like Ascletis in Greater China.[1][3]
Headquartered in San Mateo, California, Sagimet operates as a single-segment biotech firm focused on commercialization potential, publicly traded on NASDAQ with demonstrated growth momentum through successful trial completions and regulatory progress as of early 2024.[1][2][3]
Founded in 2006 as 3-V Biosciences, Inc., Sagimet Biosciences rebranded in August 2019 to reflect its sharpened focus on FASN inhibitors for metabolic diseases.[1][4] The company emerged from early research into lipid metabolism pathways, evolving from broader biopharma efforts to a specialized pipeline targeting palmitate overproduction in conditions like MASH.[3] Key leadership includes CEO and President David A. Happel (since 2022), Non-Executive Chairman George W. Kemble (since 2011), and Lead Independent Director Beth C. Seidenberg (since 2007), with recent additions like independent directors in 2024 bringing expertise in pharma and governance.[1] Pivotal moments include positive Phase 2a (FASCINATE-1) and Phase 2b (FASCINATE-2) data for denifanstat in 2023-2024, enabling FDA Breakthrough designation and Phase 3 planning.[3]
Sagimet rides the MASH/NASH market wave, a booming area in biopharma as metabolic diseases surge with obesity epidemics—projected to affect 30-40% of adults globally, driving demand for fibrosis-targeting therapies amid few approved options.[3] Timing aligns with FDA's push for non-invasive endpoints and Breakthrough designations, positioning denifanstat ahead of competitors in a $30B+ addressable market; lipid metabolism dysregulation also fuels synergies in oncology and dermatology.[1][2] Sagimet influences the ecosystem by validating FASN as a platform for multiple indications, inspiring similar precision metabolism plays and partnering (e.g., Ascletis) to expand geographically, while its public status (NASDAQ: SGMT) attracts investment into de-risked clinical assets.[3]
Sagimet's path hinges on Phase 3 initiation for denifanstat in MASH, potentially yielding data by 2026-2027 and NDA filing if successful, alongside acne and oncology readouts from TVB-3567 and preclinical advances.[3] Trends like AI-driven trial design, rising MASH awareness, and combo therapies with GLP-1s (e.g., for obesity-linked liver disease) will shape progress, amplifying its influence in precision biopharma. Success could mirror recent MASH frontrunners, scaling Sagimet from clinical player to commercial force in metabolic innovation—building directly on its FASN platform's proven momentum.[1][3]
Sagimet Biosciences has raised $194.0M in total across 7 funding rounds.
Sagimet Biosciences's investors include New Enterprise Associates, SR One, Westlake Village BioPartners, Mott Family Capital, Matthew McAviney, Robert Garland, Endeavor Venture Funds, InterWest, Polaris Partners.
Sagimet Biosciences has raised $194.0M across 7 funding rounds. Most recently, it raised $80.0M Venture Round in February 2021.